on ABIVAX (EPA:ABVX)
ABIVAX: Share and voting rights balance sheet as of October 31, 2025
On November 19, 2025, ABIVAX announced details of the number of shares and voting rights comprising its share capital as of October 31, 2025. The company, listed on Euronext Paris, has a share capital of €778,289.18, divided into 77,885,595 shares.
The total number of theoretical and exercisable voting rights amounts to 82,920,728. These figures include voting rights for private shares, in accordance with the recommendations of the AMF (French Financial Markets Authority). Theoretical voting rights are used, in particular, as the basis for calculating threshold crossings.
ABIVAX, specializing in biotechnology, continues the development of treatments for chronic inflammatory diseases, with its main candidate, obefazimod, in phase 3 for moderate to severe ulcerative colitis.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news